Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Nabumetone is a prodrug that is metabolized to an NSAID, 6-methoxy-2-naphthylacetic acid (6-MNA), structurally similar to naproxen. It is used to treat osteoarthritis and rheumatoid arthritis. Oral administration once daily.
At the time of last review, there are no published data regarding breastfeeding.
Its high percentage of fixation to plasma proteins makes its passage into milk very unlikely.
Its low oral bioavailability protects the infant from absorption.
Until more data are available on this drug in relation to breastfeeding, other safe and well-documented alternatives are preferable.
See below the information of this related product: